Literature DB >> 15624108

Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging.

Young Kon Kim1, Jeong Min Lee, Chong Soo Kim, Gyung Ho Chung, Chan Young Kim, In Hee Kim.   

Abstract

The aim of this study was to compare the diagnostic performance of gadobenate dimeglumine (Gd-BOPTA)-enhanced MR imaging, including dynamic phases and one-hour delayed phase, versus superparamagnetic iron oxide (SPIO)-enhanced imaging for detection of liver metastases. Twenty-three patients with 59 liver metastases underwent Gd-BOPTA-enhanced MR imaging (unenhanced, arterial, portal, equilibrium and one-hour delayed phase) using three-dimensional volumetric interpolated imaging and SPIO-enhanced T2-weighted turbo spin-echo and T2*-weighted gradient-echo sequences on a 1.5-T unit. Three observers independently interpreted the three sets of images, i.e. Gd-BOPTA-enhanced dynamic MRI (set 1), delayed phase imaging (set 2) and SPIO-enhanced MRI (set 3). Diagnostic accuracy was evaluated using the alternative-free response receiver operating chracteristic (ROC) analysis. Sensitivity and positive predictive value were also evaluated. The mean accuracy (Az values) and sensitivity of Gd-BOPTA-enhanced delayed phase imaging (0.982, 95.5%) were comparable to those of SPIO-enhanced imaging (0.984, 97.2%). In addition, Az values and sensitivities of both imaging sets were significantly higher than those of Gd-BOPTA-enhanced dynamic images (0.826, 77.4%: p<0.05). There was no significant difference in the positive predictive value among the three image sets. Gd-BOPTA-enhanced delayed phase imaging showed comparable diagnostic performance to SPIO-enhanced imaging for the detection of liver metastases, and had a better diagnostic performance than Gd-BOPTA-enhanced dynamic images.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15624108     DOI: 10.1007/s00330-004-2570-3

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  32 in total

1.  Multihance clinical pharmacology: biodistribution and MR enhancement of the liver.

Authors:  A Spinazzi; V Lorusso; G Pirovano; P Taroni; M Kirchin; A Davies
Journal:  Acad Radiol       Date:  1998-04       Impact factor: 3.173

2.  Detection of focal hepatic masses: prospective evaluation with CT, delayed CT, CT during arterial portography, and MR imaging.

Authors:  J P Heiken; P J Weyman; J K Lee; D M Balfe; D Picus; E M Brunt; M W Flye
Journal:  Radiology       Date:  1989-04       Impact factor: 11.105

3.  Abdominal MR imaging with a volumetric interpolated breath-hold examination.

Authors:  N M Rofsky; V S Lee; G Laub; M A Pollack; G A Krinsky; D Thomasson; M M Ambrosino; J C Weinreb
Journal:  Radiology       Date:  1999-09       Impact factor: 11.105

4.  Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions.

Authors:  G Pirovano; A Vanzulli; L Marti-Bonmati; L Grazioli; R Manfredi; A Greco; N Holzknecht; H E Daldrup-Link; E Rummeny; B Hamm; V Arneson; L Imperatori; M A Kirchin; A Spinazzi
Journal:  AJR Am J Roentgenol       Date:  2000-10       Impact factor: 3.959

5.  Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US.

Authors:  Thomas J Vogl; Wolfram Schwarz; Stefan Blume; Michael Pietsch; Kohkan Shamsi; Martina Franz; Hartmut Lobeck; Thomas Balzer; Kelly del Tredici; Peter Neuhaus; Roland Felix; Renate M Hammerstingl
Journal:  Eur Radiol       Date:  2002-09-10       Impact factor: 5.315

6.  Gadobenate dimeglumine--a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers.

Authors:  T J Vogl; W Pegios; C McMahon; J Balzer; J Waitzinger; G Pirovano; J Lissner
Journal:  AJR Am J Roentgenol       Date:  1992-04       Impact factor: 3.959

7.  Hepatic tumors: detection and characterization at 1-T MR imaging enhanced with AMI-25.

Authors:  A Denys; L Arrive; V Servois; B Dubray; D Najmark; A Sibert; Y Menu
Journal:  Radiology       Date:  1994-12       Impact factor: 11.105

8.  Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging.

Authors:  M F Bellin; S Zaim; E Auberton; G Sarfati; J J Duron; D Khayat; J Grellet
Journal:  Radiology       Date:  1994-12       Impact factor: 11.105

9.  Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions.

Authors:  P R Ros; P C Freeny; S E Harms; S E Seltzer; P L Davis; T W Chan; A E Stillman; L R Muroff; V M Runge; M A Nissenbaum
Journal:  Radiology       Date:  1995-08       Impact factor: 11.105

10.  Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions.

Authors:  Young Kon Kim; Jeong Min Lee; Chong Soo Kim
Journal:  Eur Radiol       Date:  2003-11-05       Impact factor: 5.315

View more
  23 in total

1.  Assessment of liver metastases from colorectal adenocarcinoma following chemotherapy: SPIO-MRI versus FDG-PET/CT.

Authors:  L Bacigalupo; S Aufort; M C Eberlé; E Assenat; M Ychou; B Gallix
Journal:  Radiol Med       Date:  2010-06-23       Impact factor: 3.469

2.  MRI of colorectal cancer liver metastases: comparison of orally administered manganese with intravenously administered gadobenate dimeglumine.

Authors:  Torkel B Brismar; Nikolaos Kartalis; Christian Kylander; Nils Albiin
Journal:  Eur Radiol       Date:  2011-09-28       Impact factor: 5.315

3.  Malignant focal liver lesions at contrast-enhanced ultrasonography and magnetic resonance with hepatospecific contrast agent.

Authors:  M D'Onofrio; S Crosara; R De Robertis; S Canestrini; V Cantisani; G Morana; R Pozzi Mucelli
Journal:  Ultrasound       Date:  2013-12-13

Review 4.  Enabling individualized therapy through nanotechnology.

Authors:  Jason H Sakamoto; Anne L van de Ven; Biana Godin; Elvin Blanco; Rita E Serda; Alessandro Grattoni; Arturas Ziemys; Ali Bouamrani; Tony Hu; Shivakumar I Ranganathan; Enrica De Rosa; Jonathan O Martinez; Christine A Smid; Rachel M Buchanan; Sei-Young Lee; Srimeenakshi Srinivasan; Matthew Landry; Anne Meyn; Ennio Tasciotti; Xuewu Liu; Paolo Decuzzi; Mauro Ferrari
Journal:  Pharmacol Res       Date:  2010-01-05       Impact factor: 7.658

5.  Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist(®))-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre.

Authors:  V O Chan; J P Das; J F Gerstenmaier; J Geoghegan; R G Gibney; C D Collins; S J Skehan; D E Malone
Journal:  Ir J Med Sci       Date:  2012-03-17       Impact factor: 1.568

6.  Imaging of pancreatic ductal adenocarcinoma: State of the art.

Authors:  Eric Peter Tamm; Priya Ranjit Bhosale; Raghu Vikram; Leonardo Pimentel de Almeida Marcal; Aparna Balachandran
Journal:  World J Radiol       Date:  2013-03-28

7.  The added value of contrast-enhanced ultrasound in patients with colorectal cancer undergoing preoperative evaluation with extensive gadobenate dimeglumine liver MRI.

Authors:  Nikolaos Kartalis; Torkel B Brismar; Laszlo Mihocsa; Bengt Isaksson; Nils Albiin
Journal:  Eur Radiol       Date:  2011-05-27       Impact factor: 5.315

Review 8.  Imaging diagnosis of colorectal liver metastases.

Authors:  Ling-Hui Xu; San-Jun Cai; Guo-Xiang Cai; Wei-Jun Peng
Journal:  World J Gastroenterol       Date:  2011-11-14       Impact factor: 5.742

Review 9.  Non-invasive diagnostic imaging of colorectal liver metastases.

Authors:  Pier Paolo Mainenti; Federica Romano; Laura Pizzuti; Sabrina Segreto; Giovanni Storto; Lorenzo Mannelli; Massimo Imbriaco; Luigi Camera; Simone Maurea
Journal:  World J Radiol       Date:  2015-07-28

Review 10.  Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine.

Authors:  Xue-Qing Zhang; Xiaoyang Xu; Nicolas Bertrand; Eric Pridgen; Archana Swami; Omid C Farokhzad
Journal:  Adv Drug Deliv Rev       Date:  2012-08-17       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.